Cytokinetics Inc (Cytokinetics) is a biopharmaceutical company focused on discovering, developing, and commercializing novel muscle activators and inhibitors as potential treatments for diseases where muscle performance is compromised. The company is engaged in the development of muscle-directed investigational medicines aimed at improving the healthspan of individuals with cardiovascular and neuromuscular diseases. Cytokinetics operates within the biopharmaceutical industry, specifically targeting muscle biology and the mechanics of muscle performance.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Cytokinetics's R&D focuses on advancing muscle-directed potential treatments for diseases characterized by compromised muscle function, muscle weakness, and fatigue. The company's R&D initiatives include the discovery and development of small molecule drug candidates specifically engineered to impact muscle function and contractility. The research and development activities are centered around muscle contractility, with programs in cardiac and skeletal muscle contractility, as well as novel treatments for disorders involving muscle function beyond contractility. The company is also evaluating potential treatments for heart failure with preserved and reduced ejection fraction, hypertrophic cardiomyopathy, and amyotrophic lateral sclerosis. The R&D unit of Cytokinetics is responsible for managing the company's research and development activities, which include conducting preclinical and clinical trials, optimizing pharmacokinetic properties, and ensuring compliance with regulatory requirements. The unit plays a crucial role in the discovery and development of investigational products at various stages of research and development. The company is doing clinical trial for formulation of oHCM, Pediatric oHCM, nHCM, HFpEF, Omecamtiv Mecarbil and CK-089. In FY2025, the company incurred expenses of US$416 million on its R&D activities, which grew 18.4% YoY.